Tislelizumab after colon surgery for dMMR stage II–III cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests tislelizumab given after colon cancer surgery to lower the risk of the cancer coming back. It is for people with stage II or III colon cancer that has defective mismatch repair (dMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can take part in cancer treatment studies
- Your performance status is ECOG 0 or 1 (you’re up and about most of the day)
- Your colon cancer was fully removed by surgery with clear margins (no tumor left behind at the cut edge)
- Your tumor is stage II or III colon cancer (not rectal cancer) and has confirmed dMMR
- Your scans after surgery show no spread to other organs (no metastases)
- You have not had chemotherapy, radiation, immunotherapy, biologic, or targeted therapy for this colon cancer (except 1 cycle of mFOLFOX6)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
This Phase 2 trial studies whether adding tislelizumab to standard chemo (CAPOX) around the time of surgery can lower the risk of colon or rectal cancer coming back. It’s for people with stage II or III tumors that have an MSI-H or dMMR test result, which may mean they’re more likely to respond to immune-based treatment.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.